Balyasny Asset Management LLC Cogent Biosciences, Inc. Transaction History
Balyasny Asset Management LLC
- $54.9 Billion
- Q2 2024
A detailed history of Balyasny Asset Management LLC transactions in Cogent Biosciences, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 44,441 shares of COGT stock, worth $477,740. This represents 0.0% of its overall portfolio holdings.
Number of Shares
44,441Holding current value
$477,740% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding COGT
# of Institutions
159Shares Held
114MCall Options Held
104KPut Options Held
163K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct10.5MShares$113 Million0.24% of portfolio
-
Commodore Capital LP New York, NY9.74MShares$105 Million7.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.26MShares$99.5 Million6.08% of portfolio
-
Black Rock Inc. New York, NY7.29MShares$78.4 Million0.0% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.96MShares$74.9 Million8.79% of portfolio
About Cogent Biosciences, Inc.
- Ticker COGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,758,300
- Market Cap $707M
- Description
- Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found ...